Business
Directorate Changes
Directorate Changes.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 4561H Open Orphan PLC 01 August 2019 \n\n01 August 2019\n \nOpen Orphan plc\n(\"Open Orphan\" or \"the Company\")\nDirectorate Changes\nNew Independent Non-Executive Director\nOpen Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the appointment to the board of David Kelly as an Independent Non-Executive Director. \nDavid has extensive orphan drug company experience both in Europe and in the USA. He was Executive Vice President and Managing Director of Ireland at Horizon Therapeutics plc, a biopharmaceutical company listed on Nasdaq and headquartered in Dublin. David has an excellent combination of experience having worked in larger product focussed pharmaceutical companies and also in turning around smaller pharmaceutical companies. For example, he and his colleagues transformed AGI Therapeutics before selling it to Vidara Therapeutics which in turn was acquired by Horizon Therapeutics plc, a company with a current market capitalisation of $4.5 billion.\nDavid also served as Senior Vice President of Warner Chilcott, a fully integrated specialty pharmaceutical company. While at Warner Chilcott, he led the company's successful IPO on Nasdaq. In addition, David also held roles in Elan Corporation and KPMG.\nWith David joining the Board and following the completion of the Company's acquisition of Open Orphan DAC, Tony Richardson has stepped down from the Board with effect from today. The Company would like to thank him for his service as a Director.\nProfessor Brendan Buckley, Chairman, Open Orphan, commented:\n\"We are delighted that David is joining the Board of Open Orphan. He has extensive experience in the orphan drug market and we are looking forward to having David work closely with management going forward as we seek to rapidly grow the company.\"\n \nThe following additional information is provided in accordance with paragraph (g) of Schedule Two to the AIM Rules for Companies and paragraph (g) of Schedule Two of the Euronext Growth Rules for Companies:\n \nFull name: David George Kelly \nAge: 58\nCurrent Directorships / Partnerships: Iterum Therapeutics plc, Iterum Therapeutics International Limited, Andromeda Biotech Limited, Horizon Pharma Israel Holding Corp. Limited, Horizon Pharma Investment Limited, Horizon Pharma...